REVERCE: Randomized Phase II Study of Regorafenib Followed by Cetuximab Versus the Reverse Sequence for Metastatic Colorectal Cancer Patients Previously Treated With Fluoropyrimidine, Oxaliplatin, and Irinotecan

被引：0
|
作者：
不详
机构：
来源：
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY | 2018年 / 16卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：12 / 14
页数：3
相关论文
共 50 条
  • [21] Multicenter Phase II Study of Cetuximab Plus Irinotecan in Metastatic Colorectal Carcinoma Refractory to Irinotecan, Oxaliplatin and Fluoropyrimidines
    Tahara, Makoto
    Shirao, Kuniaki
    Boku, Narikazu
    Yamaguchi, Kensei
    Komatsu, Yoshito
    Inaba, Yoshitaka
    Arai, Tatsuhiro
    Mizunuma, Nobuyuki
    Satoh, Taroh
    Takiuchi, Hiroya
    Nishina, Tomohiro
    Sakata, Yuh
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2008, 38 (11) : 762 - 769
  • [22] Outcome of cetuximab plus irinotecan in relation to RAS and BRAF mutational status in patients with colorectal cancer prior treated with a fluoropyrimidine, oxaliplatin and irinotecan
    Palshof, Jesper Andreas
    Christensen, Troels Dreier
    Poulsen, Tim Svendstrup
    Jensen, Benny Vittrup
    Linnemann, Dorte
    Schou, Jakob Vasehus
    Pfeiffer, Per
    Yilmaz, Mette K. N.
    Christensen, Ib Jarle
    Hogdall, Estrid V.
    Nielsen, Dorte
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [23] Phase II study of gefitinib, fluorouracil, leucovorin, and oxaliplatin therapy in previously treated patients with metastatic colorectal cancer
    Kuo, T
    Cho, CD
    Halsey, J
    Wakelee, HA
    Advani, RH
    Ford, JM
    Fisher, GA
    Sikic, BI
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (24) : 5613 - 5619
  • [24] Multicenter phase II study of fixed sequences of capecitabine combined with oxaliplatin or irinotecan in patients with previously untreated metastatic colorectal cancer
    Cassinello, Javier
    Valero Alvarez, Jose
    Garcia Lopez, Maria Jose
    Pujol, Eduardo
    Colmenarejo, Antonio
    Segovia, Femando
    Marcos, Fernando
    Filipovich, Elena
    Arcediano, Alberto
    Garcia Castro, Ines
    CLINICAL COLORECTAL CANCER, 2006, 5 (06) : 429 - 435
  • [25] A phase I study of the combination of panitumumab and bevacizumab in KRAS wild-type colorectal cancer patients previously treated with fluoropyrimidine, oxaliplatin, irinotecan and bevacizumab
    Takahashi, Naoki
    Iwasa, Satoru
    Fukahori, Masaru
    Sudo, Kazuki
    Sasaki, Yusuke
    Shoji, Hirokazu
    Honma, Yoshitaka
    Okita, Natsuko Tsuda
    Takashima, Atsuo
    Hamaguchi, Tetsuya
    Boku, Narikazu
    Shimada, Yasuhiro
    Honda, Kazufumi
    Yamada, Tesshi
    Yamada, Yasuhide
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2016, 78 (03) : 567 - 575
  • [26] A phase I study of the combination of panitumumab and bevacizumab in KRAS wild-type colorectal cancer patients previously treated with fluoropyrimidine, oxaliplatin, irinotecan and bevacizumab
    Naoki Takahashi
    Satoru Iwasa
    Masaru Fukahori
    Kazuki Sudo
    Yusuke Sasaki
    Hirokazu Shoji
    Yoshitaka Honma
    Natsuko Tsuda Okita
    Atsuo Takashima
    Tetsuya Hamaguchi
    Narikazu Boku
    Yasuhiro Shimada
    Kazufumi Honda
    Tesshi Yamada
    Yasuhide Yamada
    Cancer Chemotherapy and Pharmacology, 2016, 78 : 567 - 575
  • [27] Phase II Study of S-1 and Irinotecan Plus Bevacizumab as Second-line Treatment for Patients With Metastatic Colorectal Cancer Resistant to the Fluoropyrimidine-oxaliplatin-cetuximab Regimen
    Tanioka, Hiroaki
    Shimada, Ken
    Tsuji, Akihito
    Kochi, Mitsugu
    Kim, Ho Min
    Takahashi, Takao
    Denda, Tadamichi
    Takagane, Akinori
    Watanabe, Takanori
    Kotaka, Masahito
    Nakamura, Masato
    Sunakawa, Y. U.
    Takeuchi, Masahiro
    Ichikawa, Wataru
    Fujii, Masashi
    ANTICANCER RESEARCH, 2022, 42 (05) : 2675 - 2681
  • [28] Phase I study of cetuximab, irinotecan, and vandetanib (ZD6474) in previously treated metastatic colorectal cancer (mCRC).
    Meyerhardt, J. A.
    Schrag, D.
    Kulke, M.
    Enzinger, P. C.
    Chan, J. A.
    Blaszkowsky, L. S.
    Goldstein, M.
    Allen, B.
    Regan, E.
    Abrams, T. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [29] Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines
    Lenz, Heinz-Josef
    Van Cutsem, Eric
    Khambata-Ford, Shirin
    Mayer, Robert J.
    Gold, Philip
    Stella, Philip
    Mirtsching, Barry
    Cohn, Allen L.
    Pippas, Andrew W.
    Azarnia, Nozar
    Tsuchihashi, Zenta
    Mauro, David J.
    Rowinsky, Eric K.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (30) : 4914 - 4921
  • [30] A phase II study of capecitabine, irinotecan, and bevacizumab in patients with previously untreated metastatic colorectal cancer
    Renouf, Daniel J.
    Welch, Stephen
    Moore, Malcolm J.
    Krzyzanowska, Monika K.
    Knox, Jennifer
    Feld, Ronald
    Liu, Geoffrey
    MacKay, Helen
    Petronis, Jennifer
    Wang, Lisa
    Chen, Eric
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 69 (05) : 1339 - 1344
12345